The National Institute for Occupational Safety and Health (NIOSH) made a revision to the list of hazardous drugs found in health care facilities. The latest update, made in late November, now accounts for workers’ exposure risks, and now categorizes drugs by type. [click to continue…]
January 1 marks the beginning of phased-in implementation of the FDA’s tracking and pedigree regulations for medications, while the first major pharmacy requirements go into effect in July.
Beginning this month, drug manufacturers and distributors must provide pharmacies with specific transaction information. They must provide a transaction history and statement that indicates product shipments down to the lot level. This change is a result of the Drug Supply Chain Security Act of 2013. [click to continue…]
This is the perfect time for doctors and pharmacists to raise awareness about how women can protect themselves from the human papillomavirus, better known as HPV, and cervical cancer. HPV is not only a major cause of cervical cancer – it is also the most commonly diagnosed sexually transmitted disease. An estimated 79 million Americans are living with HPV, and many of them don’t realize they are infected. [click to continue…]
The combination therapy in a polypill approach for patients with cardiovascular disease received favor from various FDA officials and agency advisors. The polypill combination therapy concept has been around for a decade, but is not in use at this point. [click to continue…]
The Food and Drug Administration (FDA) recently approved a combination medication, netupitant-palonosetron, to prevent nausea and vomiting in patients receiving chemotherapy. Known as Akynzeo, the medication uses both the neurokinin-1 receptor antagonist netupitant and the serotonin type 3-receptor antagonist palonosetron. Each capsule has three 100-mg netupitant tablets, and one 0.56 mg palonosetron hydrochloride capsule. The medication can be taken with or without food. [click to continue…]
Last month, pharmaceutical manufacturer Hospira announced the voluntary recall of “dozens of product lots,” including a single lot of lidocaine hydrochloride injection, and several lots of injectable products in flexible IV containers.
Hospira recalled lot 40-316-DK of their 30-mL 1% lidocaine hydrochloride injection single dose vials after a report of human hair attached to the stopper one vial was confirmed. The company is investigating the cause of the problem at this time. [click to continue…]